Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 15/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 14/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 12/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 12/20 | 0.53 |
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
| ▸ | PDE1A | P54750 | 1/20 | 0.42 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.42 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30530004 | 0.92 | PDE4B (0.60) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL7363289 | 0.92 | PDE4B (0.60) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL7363845 | 0.91 | PDE4A (0.61) | PDE4APDE4BPDE4CPDE4DPOLB | |
| SCHEMBL7352136 | 0.82 | PDE4A (0.54) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8574005 | 0.82 | PDE4A (0.54) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7366942 | 0.82 | PDE4A (0.60) | PDE4APDE4BPDE4CPDE4DPOLB | |
| SCHEMBL7367621 | 0.82 | PDE4A (0.60) | PDE4APDE4BPDE4CPDE4DPOLB | |
| SCHEMBL7365069 | 0.82 | PDE4A (0.60) | PDE4APDE4BPDE4CPDE4DPOLB | |
| SCHEMBL8570355 | 0.80 | PDE4A (0.49) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL7358584 | 0.79 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1992019594-A1 | PYRROLIDINONES | SMITHKLINE BEECHAM CORPORATION (US) | 1992-11-12 | — | — | WO | disclosed |